EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Risk of acute pancreatitis with DPP ‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Takashi Tatewaki iD, Akira Okada iD, Yuya Kimura, Hideo Yasunaga

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70490 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Takashi Tatewaki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Pancreatitis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Association for Diabetes Education and Care, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals. Materials and methods In this target trial emulation study of medication‐naïve individuals with diabetes from a Japanese claims database from April 2014 to August 2023, the risk of acute pancreatitis was compared between new users of DPP‐4is and new users of SGLT2is. After adjusting for confounders using propensity score‐based overlap weighting, we used Cox proportional hazards models for hospitalization due to acute pancreatitis to estimate the hazard ratio (HR) and 95% confidence interval (CI) within the groups in both the intention‐to‐treat and per‐protocol analyses. We also calculated incidence rate differences (IRDs) per 1000 person‐years.

Results

This study included 26 133 DPP4‐i and 6497 SGLT2i users. DPP‐4i use was not significantly associated with a higher risk of acute pancreatitis compared with SGLT2i use; the adjusted HRs were 0.97 (95% CI, 0.51–1.83) and 1.11 (95% CI, 0.54–2.27), with IRDs of −0.05 (95% CI, −0.97 to 0.87) and 0.15 (95% CI, −0.86 to 1.15) per 1000 person‐years in the intention‐to‐treat and per‐protocol analyses, respectively.

Conclusions

Although small differences cannot be excluded given the width of the CIs for the estimated HRs, the small IRDs observed suggest that any potential difference, if present, is likely to be clinically modest. Therefore, acute pancreatitis risk may not be a major determinant when selecting initial therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsPancreatitisDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansFemaleMaleMiddle AgedAgedJapanAcute DiseaseAdultIncidenceRisk Factors

Stichwörter der Autor:innen

DPP‐IV inhibitorSGLT2 inhibitorobservational studypharmaco‐epidemiology

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  • Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Takashi Tatewaki, Akira Okada

Förderung

  • Japan Association for Diabetes Education and Care
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Tatewaki, T., Okada, A., Kimura, Y., & Yasunaga, H. (2026). Risk of acute pancreatitis with DPP ‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70490

Vancouver

Tatewaki T, Okada A, Kimura Y, Yasunaga H. Risk of acute pancreatitis with DPP ‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70490

BibTeX
@article{Tatewaki2026,
  author = {Tatewaki, Takashi and Okada, Akira and Kimura, Yuya and Yasunaga, Hideo},
  title = {Risk of acute pancreatitis with DPP ‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70490}
}
Kostenlos starten →